Ciprofibrate - Misplaced Pages

Chemical compound Pharmaceutical compound

Ciprofibrate
Clinical data

AHFS/Drugs.com	International Drug Names
ATC code	C10AB08 (WHO)
Identifiers
IUPAC name (RS)-2--2- methylpropanoic acid
CAS Number	52214-84-3
PubChem CID	2763
IUPHAR/BPS	3438
ChemSpider	2661
UNII	F8252JGO9S
KEGG	D03521
ChEBI	CHEBI:50867
ChEMBL	ChEMBL557555
CompTox Dashboard (EPA)	DTXSID8020331
ECHA InfoCard	100.052.478
Chemical and physical data
Formula	C₁₃H₁₄Cl₂O₃
Molar mass	289.15 g·mol
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES ClC2(Cl)CC2c1ccc(OC(C(=O)O)(C)C)cc1
InChI InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17) Key:KPSRODZRAIWAKH-UHFFFAOYSA-N
(verify)

Ciprofibrate is a fibrate that was developed as a lipid-lowering agent.

It was patented in 1972 and approved for medical use in 1985.

References

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 474. ISBN 9783527607495.

Lipid-lowering agents (C10)

GI tract

Cholesterol absorption inhibitors, NPC1L1	Ezetimibe Hyzetimibe SCH-48461
Bile acid sequestrants/resins (LDL)	Colesevelam Colestilan Colestipol Colestyramine Colextran Soluble fiber such as psyllium and glucomannan

Liver

Statins (HMG-CoA reductase, LDL)	Atorvastatin Cerivastatin Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin
Niacin and derivatives (HDL and LDL)	Acipimox Aluminium nicotinate Niacin Niceritrol Nicofuranose Nicotinyl alcohol
MTTP inhibitors (VLDL)	Dirlotapide Lomitapide Mitratapide
ATP citrate lyase inhibitors (LDL)	Bempedoic acid
Thyromimetics (VLDL)	Dextrothyroxine Resmetirom

Blood vessels

PPAR agonists (LDL)

Fibrates	Aluminium clofibrate Bezafibrate Choline fenofibrate Ciprofibrate Clinofibrate Clofibrate Clofibride Etofibrate Fenofibrate Gemfibrozil Nafenopin Pemafibrate Ronifibrate Simfibrate
Others	GW501516

CETP inhibitors (HDL)

PCSK9 inhibitors (LDL)

ANGPTL3 inhibitors (LDL/HDL)

Evinacumab

Combinations

Other

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

v t e PPARTooltip Peroxisome proliferator-activated receptor modulators
PPARαTooltip Peroxisome proliferator-activated receptor alpha	Agonists: 15-HETE 15-HpETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Chiglitazar Clofibrate CP-775146 Daidzein DHEA (prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil GW-7647 Lanifibranor Leukotriene B₄ LG-101506 LG-100754 Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone WY-14643 Antagonists: GW-6471 MK-886
PPARδTooltip Peroxisome proliferator-activated receptor delta	Agonists: 15-HETE 15-HpETE Arachidonic acid Bezafibrate Daidzein Elafibranor Fonadelpar Genistein GW-0742 GW-501516 L-165,041 Lanifibranor LG-101506 Seladelpar Sodelglitazar Tetradecylthioacetic acid Antagonists: FH-535 GSK-0660 GSK-3787
PPARγTooltip Peroxisome proliferator-activated receptor gamma	Agonists: 5-Oxo-ETE 5-Oxo-15-hydroxy-ETE 15-Deoxy-Δ-prostaglandin J₂ 15-HETE 15-HpETE Aleglitazar Arachidonic acid Balaglitazone Berberine Bezafibrate Cannabidiol Cevoglitazar Chiglitazar Ciglitazone Daidzein Darglitazone Edaglitazone Efatutazone Englitazone Etalocib Farglitazar Genistein GW-1929 Ibuprofen Imiglitazar Indeglitazar Lanifibranor LG-100268 LG-100754 LG-101506 Lobeglitazone Muraglitazar (muroglitazar) nTZDpa Naveglitazar Netoglitazone Oxeglitazar Peliglitazar Pemaglitazar Perfluorononanoic acid Pioglitazone Prostaglandin J₂ Ragaglitazar Reglitazar Rivoglitazone Rosiglitazone RS5444 Saroglitazar Sipoglitazar Sodelglitazar Telmisartan Tesaglitazar Troglitazone SPPARMsTooltip Selective PPARγ modulator: BADGE EPI-001 INT-131 MK-0533 S26948 Antagonists: FH-535 GW-9662 SR-202 T-0070907 Unknown: SR-1664
Non-selective	Agonists: Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: